Background <p>Postoperative endophthalmitis is a rare but severe complication of cataract surgery. Intracameral moxifloxacin prophylaxis has been widely adopted, but concerns remain regarding bacterial resistance and clinical outcomes. This study aimed to evaluate the impact of intracameral moxifloxacin prophylaxis on endophthalmitis incidence, microbiological patterns, antibiotic resistance, and visual outcomes in a university hospital setting, with comparison to a private hospital cohort.</p> Methods <p>This retrospective cohort study analyzed 21,178 cataract surgeries performed at a university hospital (2014–2023). The incidence of endophthalmitis, microbiological profiles, resistance patterns, and visual acuity outcomes (LogMAR) were assessed. Intracameral moxifloxacin prophylaxis was introduced in 2019. A comparative analysis was conducted with 19,360 surgeries from a private hospital. Fisher’s exact test, Mann-Whitney U test, and Joinpoint regression were used for statistical analysis.</p> Results <p>Endophthalmitis incidence at the university hospital was 0.109% (23/21,178 surgeries), significantly higher than the 0.021% incidence in the private hospital (<i>p</i> = 0.002). Post-prophylaxis, infection rates declined from 0.219% in 2016 to 0.042% in 2023 (<i>p</i> = 0.003). <i>Staphylococcus epidermidis</i> predominated (52.6%), and moxifloxacin resistance remained stable (pre: 45.5%; post: no increase).</p> Conclusions <p>Intracameral moxifloxacin significantly reduced endophthalmitis incidence without increasing bacterial resistance. Post-prophylaxis infection rates aligned with national surveillance benchmarks (e.g., SES-SP threshold of 0.07%), reinforcing the efficacy of this preventive strategy in a public university setting. The worsening of final visual acuity post-prophylaxis underscores the need for continued clinical vigilance. Ongoing microbiological surveillance remains essential.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Intracameral antibiotic prophylaxis and surgical expertise: key determinants in endophthalmitis after cataract surgery

  • Vinicius Campos Bergamo,
  • Luis Filipe Nakayama,
  • Nilva Simeren Bueno de Moraes,
  • Caio Vinicius Saito Regatieri,
  • Ivan Maynart Tavares,
  • Mauro Silveira de Queiroz Campos,
  • Ana Luisa Hofling-Lima,
  • Maurício Maia

摘要

Background

Postoperative endophthalmitis is a rare but severe complication of cataract surgery. Intracameral moxifloxacin prophylaxis has been widely adopted, but concerns remain regarding bacterial resistance and clinical outcomes. This study aimed to evaluate the impact of intracameral moxifloxacin prophylaxis on endophthalmitis incidence, microbiological patterns, antibiotic resistance, and visual outcomes in a university hospital setting, with comparison to a private hospital cohort.

Methods

This retrospective cohort study analyzed 21,178 cataract surgeries performed at a university hospital (2014–2023). The incidence of endophthalmitis, microbiological profiles, resistance patterns, and visual acuity outcomes (LogMAR) were assessed. Intracameral moxifloxacin prophylaxis was introduced in 2019. A comparative analysis was conducted with 19,360 surgeries from a private hospital. Fisher’s exact test, Mann-Whitney U test, and Joinpoint regression were used for statistical analysis.

Results

Endophthalmitis incidence at the university hospital was 0.109% (23/21,178 surgeries), significantly higher than the 0.021% incidence in the private hospital (p = 0.002). Post-prophylaxis, infection rates declined from 0.219% in 2016 to 0.042% in 2023 (p = 0.003). Staphylococcus epidermidis predominated (52.6%), and moxifloxacin resistance remained stable (pre: 45.5%; post: no increase).

Conclusions

Intracameral moxifloxacin significantly reduced endophthalmitis incidence without increasing bacterial resistance. Post-prophylaxis infection rates aligned with national surveillance benchmarks (e.g., SES-SP threshold of 0.07%), reinforcing the efficacy of this preventive strategy in a public university setting. The worsening of final visual acuity post-prophylaxis underscores the need for continued clinical vigilance. Ongoing microbiological surveillance remains essential.